Merck, Sharpe & Dohme (Australia) Pty Ltd. v Genentech, Inc

Link copied
Case Copied 44 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Merck, Sharpe & Dohme (Australia) Pty Ltd. v Genentech, Inc. [2014] APO 6

Patent Application:                   2003287257

Title:Inhibition of IL-17 production

Patent Applicant:  Genentech, Inc.

Opponent:  Merck, Sharpe & Dohme (Australia) Pty Ltd.

Delegate:  Dr B Akhurst

Decision Date:  6 February 2014

Hearing Date:  12 November 2013, in Canberra

Catchwords:  PATENTS - section 59 opposition - novelty - lack of novelty by inevitable outcome - priority date deferred - lack of novelty over the specification intended for grant in Europe - inventive step - documents would not be ascertained - fair basis - no real and reasonably clear disclosure of a therapeutic method involving testing all subjects to determine they had elevated level of expression of IL-17 prior to treatment - grounds relating to manner of manufacture, useful, clarity, full description and claims define the invention not established

Representation:  Patent applicant:  Andrew Fox of Counsel, instructed by Dr Stuart Boyer of Griffith Hack, Perth.

Opponent: Matthew Darke of Counsel, instructed by Dr Andrew Blattman and Dr Simon Potter of Spruson & Ferguson, Sydney.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2003287257

Title:Inhibition of IL-17 production

Patent Applicant:  Genentech, Inc.

Date of Decision:  6 February 2014

DECISION

The opposition succeeds.  The invention of claims 1-5, 11-12 and 14-33 lacks novelty.  Claim 15 and all its dependent claims lack fair basis, insofar as these claims require each individual subject to be tested to determine an elevated level of IL-17 expression prior to treatment with the IL-23 antagonist.

Genentech is allowed 2 months from the date of this decision to file amendments to overcome the deficiencies in the claims.

Costs are awarded according to Schedule 8 against Genentech, Inc.

REASONS FOR DECISION

Background

  1. Patent application 2003287257 was filed by Genentech, Inc. (Genentech) via the PCT on 29 October 2003 claiming priority from provisional application US 60/423,090 filed on 30 October 2002.

  2. After examination, the application was advertised as accepted on 10 December 2009.  Merck, Sharpe & Dohme (Australia) Pty Ltd. (MSDA) filed a notice of opposition on 10 March 2010 and served the statement of grounds and particulars on 10 June 2010.  After extensions were granted for each evidentiary stage, evidence in support was completed on 29 September 2011, evidence in answer by 2 August 2012 and evidence in reply on 4 February 2013.  

    Evidence

  3. The evidence in support of the opposition consists of declarations by:

    ·    Andrew Nathaniel Blattman dated 28 July 2010 with Exhibits ANB-1 to ANB-36

    ·    Stuart Graham Tangye dated 3 December 2010 (Tangye#1) with Exhibits SGT-1 to SGT-23

    ·    Stuart Graham Tangye dated 28 June 2011 (Tangye#2) with exhibits SGT-24 to SGT-28

    ·    Stuart Graham Tangye dated 28 September 2011 (Tangye#3)

  4. The evidence in answer consists of declarations by:

    ·    Stuart James Boyer dated 2 July 2012 with exhibits SJB-1 to SJB-14

    ·    Stuart James Boyer dated 31 July 2012 with exhibits SJB-15 to SJB-19

    ·    Wenjun Ouyang dated 7 March 2012 (Ouyang) with exhibits A to O

  5. The evidence…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merck, Sharpe & Dohme (Australia) Pty Ltd. v Genentech, Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] APO 6
Decision Date

CaseChat Overview and Summary

The opposition to the grant of a patent was filed by Merck, Sharpe & Dohme (Australia) Pty Ltd. (MSDA) against Genentech, Inc. MSDA opposed the patent on the basis that the invention lacked novelty and was obvious, was not useful, and did not comply with statutory requirements including that it was not fully described, and the claims were not clear or fairly based on the specification. The patent was opposed by MSDA on the basis of prior art documents and the specification. The opposition was heard by Dr B Akhurst. MSDA was successful in its opposition. MSDA established that the invention lacked novelty and that claims 1, 4-5, 14-15 and 11-12, 16-33 lacked fair basis. MSDA did not establish that the invention lacked utility. MSDA did not establish that the claims did not define the invention or were unclear. The costs of the opposition were awarded to MSDA. Genentech was given 2 months to amend the claims to overcome the deficiencies.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established